The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the market.
On September 23 the little-known surgical material business joined the S&P/ ASX200 (ASX: XJO) index of Australia’s leading businesses with its shares up an incredible 24x from 9 cents to $2.43 over just 5 years.
For the financial year ending June 30 2019 it posted a loss of $3.19 million on revenue of $13.7 million as it looks to increase the range of applications for its patented polymer technology NovoSorb.
It is commonly used by surgeons to treat burns or laceration victims during remedial surgery.
Polynovo is currently running what it describes as a “pivotal trial” to assist it in getting US FDA approval for its NovoSorb BTM product for the treatment of burns victims. It appears to be in the early protocol design stage for now but any hint of FDA approval for a biotech tends to set biotech investors’ pulses racing.
Other speculative biotech businesses currently exciting investors include Mesoblast Limited (ASX: MSB), Next Science Ltd (ASX: NXS), Opthea Ltd (ASX: OPT) and Paradigm Biopharmaceuticals Limited (ASX: PAR).
You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.
So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!
Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...
While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...
Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.
You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!
You can find Tom on Twitter @tommyr345
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.